MENA Oncology Conference
23rd & 24th May 2011
Intercontinental City Stars, Cairo, Egypt

KEY SPEAKERS AND PANELISTS

Professor Nada Alwan
Pioneering National Breast Cancer Research & Early Detection Program, Iraq, Executive Director

Dr Amal Samy Ibrahim
National Cancer Institute, Egypt, Professor of Epidemiology and Director of the National Cancer Registry of Egypt

Dr Heba Sweed
Global Initiative for Breast Cancer Awareness, Egypt, Country Program Manager

Professor Dr Alaa Kandil
Alexandria School of Medicine, Egypt, Professor of Clinical Oncology

Professor Dr Rabab Gaafar
National Cancer Institute, Cairo University, Egypt, Professor & Head of Medical Oncology Department & National Representative of ESMO in Egypt & Africa

Dr Sidi Mohamed Taher Alaoui
Lalla Salma Association, Morocco, President of Scientific Committee

Dr Norra H. Said
Cairo University, Egypt, Breast Radiologist and Egyptian Society of Women’s Imaging & Health Care, Treasurer

Claude Bacrie
SuperSonic Imagine, France, Co-founder and Scientific Director

Dr Khalid Taalab
Military Academy Academy IAEA, Egypt, Professor of Nuclear Medicine and PET CT Unit Manager at TechnoScan Egypt

Professor Dr Ashraf Selim
Cairo University, Egypt, Head Of Women’s Imaging Unit, Consultant of Egyptian National Breast Screening Program & President of Egyptian Society of Women’s Imaging & Health Care (ESWH)

Dr Mohamed Shaalan
Breast Cancer Foundation of Egypt, Egypt, Director

Dr. Mohsen Samy Barsoum
Cairo University, Egypt, Professor of Clinical Oncology

Dr Ilia Anis
Cairo University, Egypt, Pathologist

Dr Raghib Ali
INDOX Cancer Research Network, UK, Director

Dr Michel Daher
Lebanese Cancer Society, Lebanon, President

Dr Carlo V. Catapano
Oncology Institute of Southern Switzerland, Switzerland, Director, Experimental Oncology

Nicholas Kalavrezos
University College London Hospital, UK, Consultant, Maxillofacial/Head & Neck Surgeon

Dr Rasha Fahmi Abdalla
El-Salam Oncology Center, Egypt, Director

Dr C. S. Pramesh
Tata Memorial Hospital, India, Thoracic Surgery Head

Dr Anil Heroor
Fortis Hospital, India, Oncosurgeon

YOUR PRESTIGIOUS ADVISORY PANEL

Dr David Kerr
Sidra Medical and Research Center, Qatar, Chief Research Adviser

Dr Suad Bint Mohamed Bin Amer
King Faisal Specialist Hospital and Research Centre KSA, Saudi Arabia, Head of Breast Cancer Research Unit, Zahra Breast Cancer Association, KSA, Founder and Co-Chairman

Dr Ashraf Selim
Cairo University, Egypt, Head Of Women’s Imaging Unit, Consultant of Egyptian National Breast Screening Program & President of Egyptian Society of Women’s Imaging & Health Care (ESWH)

Dr Hussein Khaled
Cairo University, Egypt, Prof. of Medical Oncology and Vice President for Postgraduate Studies and Research

Dr Raul Ribeiro
St Jude Children research hospital, USA, Director, International Outreach Program and Leukemia / Lymphoma Division

Dr Carlo V. Catapano
Oncology Institute of Southern Switzerland, Switzerland, Director, Experimental Oncology

Dr Aida Hussein
Federal Ministry of Health, Sudan, Coordinator of the Breast Cancer Control Programme

Dr Salwa Boulos
Galla Hospital, Egypt, Breast Radiologist

Dr Ahmad Al Khatteib
King Hussein Cancer Center, Jordan, Director of Training

MEMBERS

Silver Sponsor

Bronze Sponsors

Associate sponsors

visit our website:
www.fleminggulf.com
EVENT OVERVIEW

Cancer is a major public health problem that affects every country in the MENA (Middle East & North Africa) region regardless of economic and social situation and this Conference will focus mainly on the Breast Cancer as it is the most common type of cancer in this region.

The balanced Program of these 2 Days will reveal consolidated knowledge, region-based experiences and most innovative approaches on controversial issues regarding prevention & risk of cancer, imaging & screening, new initiatives in targeted therapies, and more.

MENA Oncology Conference will be a great opportunity for governmental and non-governmental cancer control officials; for physicians, researchers and health professionals and also for patients, advocates, volunteers and others interested in cancer control, from all over the world, to get together and exchange recent views on how to deal with cancer the most effective way in 2011.

WHO WILL ATTEND?

- Medical Oncologists and Surgical Oncologists
- Radiologists and Radiation Oncologists
- Haematologists
- Pathologists
- Clinical Pharmacists
- Nurses

email: tarun.rajagopal@fleminggulf.com, www.fleminggulf.com
Day 1 | 23rd May 2011

8:30 Registration and Coffee
9:00 Opening Remarks from Fleming Group
9:10 Opening Remarks from the Chair

Regional Perspective on Breast Cancer

9:20 KEYNOTE | Introducing a Comprehensive Information System on Breast Cancer Control in the Eastern Mediterranean Region

- Breast cancer: the commonest cancer among women in countries within the Eastern Mediterranean Regions (EMR)
- Identifying other factors to increase efforts for breast cancer control: younger ages at presentation, late stages at first diagnosis, the prevalence of more aggressive tumour behavioural forms, etc.
- Fighting against high mortality/incidence ratio in these countries: most of national cancer registries in the EMR lack data regarding age-specific incidence rates, stage of disease at presentation and survival rates...
- Introduction to the comprehensive database breast cancer information (designed under supervision of International Agency for Research on Cancer to compare the demographic characteristics, clinicopathological presentations and treatment outcomes of breast cancer patients within selected countries in the Middle East including Iraq, Jordan, Lebanon and Egypt

Q & A

Professor Nada Alwan, Pioneering National Breast Cancer Research & Early Detection Program, Iraq, Executive Director

10:00 CASE STUDY | The Challenges Facing National Cancer Control Plans - Egypt Case

- Revealing main reasons of the growing cancer burden
- Challenges facing the cancer control plans
- Local strategies to overcome these hurdles

Q & A

Dr Amal Samy Ibrahim
National Cancer Institute, Egypt, Professor of Epidemiology

10:30 Morning Coffee and Networking

Focus on Fighting against Breast Cancer

11:00 The Global Initiative for Breast Cancer Awareness in Egypt

Relation between awareness and early detection of breast cancer

Dr Heba Swood, Global Initiative for Breast Cancer Awareness, Egypt, Country Program Manager

11:40 Update on the Role of Aromatase Inhibitors in the Adjuvant Treatment of Postmenopausal Breast Cancer Patients

- Highlighting the efficacy of aromatase inhibitors
- Comparison with anti-estrogen
- Upfront and sequential schedules
- Dealing with major side effects

Q & A

Professor Dr Ala’a Randill, Alexandria School of Medicine, Egypt, Professor of Clinical Oncology

12:20 Luncheon

13:30 Controversies in Neoadjuvant Therapy

- Radiation after Breast Conserving surgery
- Impact of systemic Therapy
- Postmastectomy radiation in 1-3 positive nodes

Q & A

14:10 CASE STUDY | The Moroccan ‘Lalla Salma’ Program in Early Detection and Screening for Breast Cancer

- Primary health care system: screening
- Secondary health care system: diagnosis
- Tertiary health care system: treatment
- Q & A

Dr Sidi Mohamed Taher Alaoui
Lalla Salma Association, Morocco
President of scientific Committee

14:50 Magnetic Resonance Imaging of the Breast, when & why?

- Magnetic Resonance Imaging (MRI): a noninvasive procedure, representing the most sensitive modality for the detection of invasive breast cancer in high risk patients
- Benefits of this powerful tool in diagnosing multifocality, or multicentricity, as well as contralateral malignant foci
- Helping to assess for residual invasive cancer in patients who have undergone lumpectomy with positive margins at pathology
- In assessment of post operative breast: revealing proved reliability in differentiating scar tissue from recurrence & being gold standard in evaluation of silicone implant integrity

Q & A

Dr Norran H. Said, Cairo University, Egypt
Breast Radiologist and Egyptian Society of Women’s Imaging & Health Care, Treasurer

15:30 Afternoon Tea and Networking

16:00 Shear Wave Elastography, from ultrasound technology breakthrough to Clinical benefit

Claude Bacrie, SuperSonic Imagine
Co-founder and Scientific Director

16:30 The Matchless Impact Of PET CT In Tumor Management

Professor Dr Khalid Taalab, Military Academy Academy IAEA
Professor of Nuclear Medicine and PET CT Unit Manager at TechnoScan Egypt

17:00 FOCUSED PANEL DISCUSSION: Are we over treating Small Screening detected Breast Cancers?

- Critical phases of earlier diagnosis creating a new situation in which both the diagnostic and the therapeutic team members encounter previously uncommon situations
- Guidelines for the treatment of small non palpable breast cancers which should not based on trial results obtained from palpable, clinically diagnosed cancers
- Using established methods for treating mammographically detected palpable cancers, non-palpable lesions which carry a considerable risk of over treatment, because the histologic prognostic parameters do not reliably predict the outcome of 1-14 mm invasive breast cancers

Moderator: Professor Dr Ashraf Selim
Cairo University, Egypt, Professor of Radiology, Head Of Women’s Imaging Unit, Consultant of Egyptian National Breast Screening Program & President of Egyptian Society of Women’s Imaging & Health Care (ESWIM)

Panelists: Professor Dr Ala’a Randill
Alexandria School of Medicine, Egypt, Professor of Clinical Oncology
Dr Mohamed Shaalan
Breast Cancer Foundation of Egypt, Director
Dr Mohsen Samy Barsoum
Cairo university, Egypt, Professor of Clinical Oncology
Dr Ilia Anis, Cairo University, Egypt, Pathologist

17:45 Industry Session

Representative of the New Radiant Technology, Italy

18:00 Closing Remarks from the Chair

All our Speakers and Delegates are cordially invited to attend a NETWORKING RECEPTION

Reception Host: New Radiant Technology, Italy
Day 2 | 24th May 2011

8:00 Registration and Coffee

9:00 Opening Remarks from the Chair

9:10 KEYNOTE PRESENTATION Establishing a Clinical Research Network across the MENA Region
- Clinical research as a critical tool in the fight against cancer: identifying the best treatment for individual cancer patients & helping governments and agencies develop appropriate plans and long-term strategies for cancer control and prevention
- Balancing the MENA region’s well-trained physicians, scientists and well-equipped hospitals with the very limited experience in clinical research
- Necessity of a cooperative group that facilitates collaborative research through providing a platform of action and expertise
- Establishing a Cancer Research Network across the MENA region which will conduct research, training, education, and facilitate collaboration, thereby becoming a regional leader and a major global contributor to oncology research
  - Q & A
  - Dr Raghib Ali, INDOX Cancer Research Network, UK, Director

9:50 Ethics of Biomedical Research on Human Subject
- Gaining data from scientific research: systematic collection, analysis and interpretation of data to respond to human curiosity, and answer a certain question or solve a problem
- Reengineering medical research as the application of the scientific method to medicine while raising complex ethical, legal and social issues
- Developing ethical and scientific standards for carrying such a research on human subjects in international guidelines, including the Declaration of Helsinki, the CIOMS International Ethical Guidelines for Biomedical Research Involving Human Subjects, and the WHO Guidelines for Good Clinical Practice
- Revealing the responsibility of researchers to inform themselves about the ethical, legal and policy standards that govern their activities
- Compliance with these guidelines helping to ensure that the dignity, rights, safety, and well-being of research participants
  - Q & A
  - Dr Michel Daher, Lebanese Cancer Society, Lebanon, President

10:30 Morning Coffee and Networking

11:00 Therapeutic Strategies to Target Cancer Stem Cells and Metastasis
- Challenging views and critical aspects of tumor biology
- Sharing recent research findings which highlighted the importance of tumor heterogeneity and tumor-initiating cells with stem cell-like properties in tumor initiation and progression
- Discovering multiple genetic and epigenetic factors which control normal and cancer stem cell biology and are at play in the metastatic cascade
- Availability of new therapeutic targets and strategies for devising more effective treatments of cancer
- Coping with challenges of early stages in translating the new findings into clinical applications
- Reviewing the most recent findings on the critical pathways and therapeutic strategies which are under development
  - Q & A
  - Dr Carlo V. Catapano, Oncology Institute of Southern Switzerland, Switzerland, Director, Experimental Oncology

11:40 INTERACTIVE PANEL DISCUSSION – New Perspectives in Cancer Research & Control
Moderated by:
- Dr Raghib Ali, INDOX Cancer Research Network, UK, Director
- Dr Michel Daher, Lebanese Cancer Society, Lebanon, President
- Dr Carlo V. Catapano, Oncology Institute of Southern Switzerland, Switzerland, Director, Experimental Oncology

12:10 Lunch Break

13:40 Comprehensive Surgical Management of the Head & Neck Cancer Patient
- Exposure to modern methods of surgical management of head & neck cancer
- Reconstructive challenges facing the head & neck cancer patient
- Future perspectives in the surgical treatment of these cancer types
  - Q & A
  - Nicholas Kalavrezos, University College London Hospital, UK Consultant Maxillofacial/Head & Neck Surgeon

14:20 CASE STUDY Molecular Targeted Therapies in Thyroid Tumors
- Introduction & epidemiology of thyroid Cancer & traditional therapies
- Molecular & pathological basis of thyroid cancer pathogenesis
- Novel targeted therapies for treating thyroid carcinoma
  - Q & A
  - Dr Rasha Fahmi Abdalla, El-Salam Oncology Center, Egypt Director

15:00 Afternoon Tea and Networking

15:30 Screening of Lung Cancer – The Magic Grail or Mere Hype
- Lung cancer: a disease causing more than a million deaths worldwide annually
- Most patients present in advanced stage of disease precluding potentially curative treatment
- Early screening trials with disappointing results and failing to impact mortality
- Recent trials using low dose CT scans showing promising results
- Finding the current evidence on screening for lung cancer
  - Q & A
  - Dr C.S. Pramesh, Tata Memorial Hospital, Thoracic Surgery Head

16:10 Function Preserving Surgery in Lung Neoplasms
- Need of function preserving surgery in lung diseases arises from the high morbidity and even mortality associated with pneumonectomies
- Limitations of pneumonectomy, trying to preserve as much lung as possible without copromising on oncological principles
- Presenting experience with function preserving surgery which is also known as “sleeve resection” of the lung for lung neoplasms
  - CASE STUDY Case of a carcinoid in the main bronchus which could be successfully resected with just doing a upper lobectomy and sparing the middle and lower lobes of the right lung
- Analysis of experience with the procedure and a review of the literature
  - Q & A
  - Dr Anil Heroor, Fortis Hospital, India, Oncosurgeon

16:50 FOCUSED PANEL DISCUSSION – Preventing & Treating Various Cancer Types
Moderated by:
- Dr C.S. Pramesh, Tata Memorial Hospital, Thoracic Surgery Head
- Dr Anil Heroor, Fortis Hospital, India, Oncosurgeon
- Dr Andy Smith, Hologic Inc, USA, Senior Director

17:20 Closing Remarks from the Chair

I would like to thank everyone who has helped with the research and organization of this event, especially the advisors and speakers for their support and commitment.

Doaa Said & Victoria Szoboszlai
victoria.szoboszlai@flemingeurope.com
Meet Our Prominent Speakers

Professor Nada Alwan, Pioneering Breast Cancer Research & Early Detection Program, Iraq, Executive Director

As a Professor of Pathology, directing the Breast and Cervical Cancer Research Unit (Baghdad University Medical College/MoHESR) for more than 10 years, and the Alwan Referral Training Center for Early Detection of Breast Tumour (Medical City Teaching Hospital/MOH), Dr. Alwan devoted her scientific efforts and clinical practice to early detection and screening for breast cancer in Iraq. Together with other colleagues and in collaboration with her international academic partners, she founded the National Program for Down Staging of Breast Cancer in Iraq (MOH, 2001). Since then, specialized centers and clinics for early detection of breast cancer were established all over the 18 Iraqi Governorates. She supervised several research projects focusing on updating knowledge and strengthening skills of the involved professionals. In 2008, under the umbrella of the Common Secretariat for the Council of Ministers and the Iraqi Parliament, Dr. Alwan established the “Pioneering National Breast Cancer Research Program” which is currently chaired by the Ministry of Higher Education and Scientific Research (MoHESR) that coordinates national efforts in collaboration with the concerned ministries, including Ministry of Health (MoH), Ministry of Science & Technology (MoST), Ministry of Social Affairs (MoSA), Ministry of Environment (MoE) and local NGOs. As an executive director of that national program, and following a visit to the Screening Group of the IARC Lyon (July 2009), Dr. Alwan developed, with their assistance, a comprehensive breast cancer information system. Currently, plans are designed to use that database model to compare the demographic characteristics, clinicopathological presentations and management outcomes of breast cancer patients within selected countries in the Middle East including Iraq, Jordan, Lebanon and Egypt. Within the field of adopting national cancer control strategies and establishing breast cancer early detection programs, Dr. Alwan served as an international invited speaker and national chairperson for the WHO/ICO CANCER (2009), WHO/ICO/TC (2009-2011), US MMK Breast Partnership Initiative (MFI/2007, 2009), Susan G. Komen for the Cure (2009) and the Jordanian National Breast Cancer Program (2010).

Professor Rabab Gaafar received her M.B.B.Ch. from Faculty of Medicine, Cairo University, M. Sc. General Medicine from Faculty of Medicine, Cairo University, and M.D. certification in Medical Oncology from the National Cancer Institute, Cairo University. Prof. Rabab Gaafar is directing the Thoracic Oncology Program at NCI, Cairo and she is also heading the Early Detection Prevention Unit at the Institute since 2006. She is currently chairman of Quality Assurance in the Board of the European Organization for Research and Treatment of Cancer Lung Cancer Group (EORTC). Prof. Rabab Gaafar has published more than 150 publications in National and International Journals and is in the Editorial Board for the journal of the National Cancer Institute, Cairo. Dr. Alwan received the 2009 and 2010 Award for distinguished publications in International peer-reviewed journals. She had also received previous the Medical Syndicate Award of Cairo in 2003 and that of Egypt in 2004. In the year 2009, she received Cairo University Award of appreciation for excellence. Prof Rabab Gaafar holds memberships in several professional societies including the International Association for the Study of Lung Cancer (IASLC), European Society of Medical Oncology (ESMO), Mediterranean Oncology Group (MOG), International Federation for Cancer Research and Development (IFCR) and the European Society of Medical Oncology (ESMO). Recently, she is National representative for Egypt in the Mediterranean Multidisciplinary Oncology Forum (MMOF). Prof. Rabab Gaafar is mainly interested in solid tumors mainly Lung Cancer, Mesothelioma, and Breast Cancer, targeted therapy and new drugs.

Professor Dr Alaa Kandil, Alexandria School of Medicine, Egypt, Professor of Clinical Oncology

Dr. Alaa Kandil has started his oncology profession 1982 where he was appointed as a full time resident in the department of Clinical Oncology & Nuclear medicine after which he obtained his Master degree (general Pathology Excellent). His training mainly encompasses with radiation and medical oncology programs. Shortly after this period, he had a 3 months training at St Luke’s, the Hospital, Gulfeld and the Royal Marsden Hospital, London, England. 1989, Dr Kandil went to Stanford university, California, USA where had all the work of his Doctorate degree thesis done and his thesis (drug resistance, interaction between chemotherapy & hyperthermia) was defended back home in 1991 and he passed his exams to obtain his Doctorate degree and been appointed as a lecturer in his University. 1993, Dr Kandil joined the Department of Oncology at the King Faisal Specialist Hospital (Tetray Care Center), Riyadh, Saudi Arabia for 8.5 years. Dr Kandil is full professor at the Alexandria Cancer Institute, Egypt, and Jordan Cancer Institute, Jordan. Prof. Kandil has over 30 publications in international journals and a great deal of experience in managing malignancies of the breast, head & neck, lymphomas and gynecological malignancies.

Dr Sidi Mohamed Taher Alalou, Lalma Salma Association, Morocco

President of Scientific Committee

Professor Dr Ashraf Selim, Cairo University, Egypt

Professor of Radiology, Head Of Women’s Imaging Unit, Consultant of Egyptian National Breast Screening Program & President of Egyptian Society of Women’s Imaging & Health Care (ESWII)

Dr Mohamed Shaalan, Breast Cancer Foundation of Egypt, Egypt, Director

Dr Mohsen Samy Barsoum, Cairo University, Egypt, Professor of Clinical Oncology

Dr Mohsen Samy Barsoum received his doctorate degree in clinical oncology at Cairo University, in 1977. He is currently the Professor of clinical oncology at National Cancer Institute, Cairo University. Furthermore, he is a ASCO, ESMO ASRO, ESTRO Member and contributes to the Egyptian society of oncology’s work as well.

Dr Ilia Anis, Cairo University, Egypt, Pathologist

Dr Andy Smith, Hologic Inc, USA, Senior Director

Dr Andy Smith is the Senior Director of Imaging Science for Hologic, Inc. He has been involved in medical imaging research and development for over 20 years, with a current focus on advanced breast imaging technologies such as tomosynthesis. He lectures widely around the world on breast imaging and physics, and is a co-author on over 50 patents and patent applications. He received his B.S. and Ph.D. degrees in physics from the Massachusetts Institute of Technology.
Nickolas Kalavrezos, University College London Hospital, UK
Consultant Maxillofacial/Head & Neck Surgeon

Nickolas was appointed Consultant Maxillofacial/Head & Neck Reconstructive Surgeon at UCLH in 2002. Mr Kalavrezos has a sub-specialty interest in facial and oral oncology and microvascular reconstruction. His main clinical research interests are the diagnostic and therapeutic aspects in the management of advanced head and neck cancer, and the functional and aesthetic rehabilitation of the head and neck with flap reconstruction. He provides the surgical treatment for the Head & Neck Sarcomas as the Lead Head & Neck Surgeon of the London Sarcoma Centre based at UCLH. His research interests also include the engineering for complex facial defects and robotic surgery for inaccessible areas of the head and neck.

Dr Rasha Fahmi Abdalla, El-Salam Oncology Center, Egypt, Director

Dr Rasha Fahmi Abdalla received her M.B.B.CH from faculty of medicine Ain Shams University, in 1996. He started his clinical career with a residency post in El-Salam oncology center, in 1998. He obtained M.Sc. in Radiation oncology Cairo University & M.D. in clinical oncology from Cairo University in 2007. Currently, he is a clinical oncology consultant & director of El-Salam oncology center. Professional memberships include European society of medical oncology (ESMO), Egyptian cancer society, Arab medical association against cancer, Arab palliative care consortium, Middle east cancer consortium (MECC). Due to his involvement in management since 2004 as assistant manager and deputy director in 2008 & director of the center in 2010 Dr Rasha Fahmi Abdalla is registered to have master degree in hospital management in the Arab academy for science, technology & marine transport and at present he is having Harvard executive management course for health care leaders & Financial transparency & corporate governance for health care organizations. His main research interest is in breast cancer and Dr Abdalla received the Egyptian Medical Syndicate award in 2006

Dr C. S. Pramesh, Tata Memorial Hospital, India, Thoracic Surgery Head

Dr Pramesh is an Associate professor and Head, Thoracic Surgery at Tata Memorial Hospital. He is a member of the TMC Research Administrative Council and the hospital scientific review committee. His clinical interests include esophageal and lung cancer and minimal invasive thorascopic and laparoscopic in the treatment of these cancers. He has had extensive training in clinical research methodology, biostatistics and bioinformatic. His research interests are widespread and span areas of cancer epidemiology, clinical and translational research. He is a principal investigator in several investigator initiated and industry sponsored clinical trials in thoracic oncology. He has over 80 peer reviewed journal publications and chapters in text books. The Clinical Research Secretariat, which he investigator initiated and industry sponsored clinical trials in thoracic oncology. He has over 80 peer reviewed journal publications and chapters in text books. The Clinical Research Secretariat, which he heads, has the stated mandate of facilitating and promoting investigator initiated clinical research in the centre. The CRI also organizes an annual meeting on Evidence Based Management of common cancers which has been held for the past eight years at the centre. He is keenly interested in training investigators in clinical research and organises workshops and short courses on clinical research methodology and Good Clinical Practice. He is a regular speaker in meetings and workshops on clinical research methodology and statisticians. He is an expert reviewer for several national and international journals in surgery, thoracic surgery and oncology.

Dr Anil Heroor, Fortis Hospital, India, OncoSurgeon

Dr Anil Heroor is an oncosurgeon trained at the Tata Memorial Hospital, a premier cancer institute in the country. He has completed his MBBS from the Seth G J Medical College and KEM Hospital, Mumbai. He did his general surgery training from the Seth G J Medical College and KEM Hospital, Mumbai. He was first among all the candidates at the Sion Hospital and was awarded the “Wockhardt Award” that year. After passing MBBS, he did his surgical oncology training at the Tata Memorial Hospital performing numerous cancer surgeries. His areas of interest are lung cancer surgery, medulloblastum, tumours, breast cancer including Breast conservation therapy for cancer, esophageal cancer.He has numerous publications including 17 international publications and presentations to his credit. He has received the Best Paper Award at two International Conferences for his work on Esophageal Malignancies.

Silver Sponsor - Techoscan

Techoscan is one of the leading radiology centers in Egypt, which offers diagnostic services that is of the newest technology. Techoscan was founded in 1986. In year out year, Techoscan professionals touch the lives of thousands, meeting the converging needs of patients, employees, public health authorities and corporate investors alike. Techoscan strives to create a working environment of mutual respect, encouragement and trust - one that rewards commitment and performance and that is responsive to the needs of highly qualified medical professionals. Techoscan depends on high technological equipment in all of its operations. Not just the diagnostic equipment, but also the use of information technology and networked computing in its entire operations.

Bronze Sponsor - Hologic. Preserving the Gifts of Wellness and Life.

At Hologic our focus is women’s health. Our mission is to Provide Leading Edge Technologies Targeting Women’s Health with an Emphasis on the Early Detection of Diseases – Ultimately Saving Lives. Our passion can be seen in our innovative diagnostic imaging systems for the early detection of breast cancer and osteoporosis assessment, in addition to our innovative and effective technologies in early detection of cancer cervix and treatment of mammography. We strive to continually push the boundaries of imaging to provide you with superior image quality and diagnostic accuracy. Every year, Hologic spends tens of millions of dollars in research and development to advance the field of women’s healthcare. As our clinical areas expand, we are taking on a broader range of health issues, yet our goal remains the same: to deliver innovative technologies that result in better outcomes for women. Working together we cannot fail.

Associate Sponsor - Supersonic

SuperSonic Imagine is an innovative corporation that was founded in 2005 by experts in the ultrasonic medical imaging field. SuperSonic Imagine has created a new ultrasound system named the Aixplorerâ¢, with an all-software-based architecture that allows for great speed, accuracy and flexibility. Only SuperSonic Imagine supports a new dimension in ultrasound: MultiWaveâ¢ Technology, two waves to better characterize tissue. This technology ensures impeccable images from an ultrasound wave and real-time, local tissue elasticity values in kilopascals from a shear wave, ShearWave Elastographyâ¢. The Aixplorer gives physicians the added diagnostic confidence they require.

Associate Sponsor - Fortis Healthcare Limited

Fortis Healthcare Limited is committed to clinical excellence and patient-centric healthcare, which is manifest in hospital design, patient services, medical programmes and the compassionate approach of our multidisciplinary teams. Fortis - one that rewards commitment and performance and that is responsive to the needs of highly qualified medical professionals. Our mission is to provide state-of-the-art facilities and cutting-edge technology to patients in the major medical specialties.

Lunch sponsor - The Esteé Lauder Companies Inc.

The Esteé Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products retail in the beauty area of 5,000 leading department stores and beauty shops worldwide, including 55,000 locations in over 150 countries. The company’s global sales in the fiscal year ended 30 June 2013 were $14.5 billion, of which 44% was from the Americas, 25% from Europe, 27% from the Japan/Korea region and 4% from the rest of the world. The company’s portfolio sold in over 140 countries and territories: Esteé Lauder, Aramis, Clinique, M.A.C, Bobbi Brown, Tommy Hilfiger, La Mer, Donna Karan, Jo Malone, Sean John and Tom Ford. The Esteé Lauder Companies Inc. is committed to “Bringing the Best to Everyone We Touch.” The company’s dedication to the communities in which it works and the health and wellness of its consumers and employees is ingrained in its corporate culture. One of the company’s most prominent global campaigns for corporate social responsibility is increasing awareness of breast cancer. The Breast Cancer Research Foundation® was founded in 1993 by Evelyn H. Lauder as a not-for-profit organization dedicated to funding innovative clinical and translational research. In October 2009, BCRF awarded nearly $28.5 million to 173 scientists across the United States, Latin America, Europe, the Middle East and Australia. BCRF perseveres in directing more than 85 cents on every dollar donated to research. And for the eighth consecutive year, BCRF received Charity Navigator’s highest rating, four stars, thus outperforming over 99.8% of the 5,400 evaluated charities, while the American Institute of Philanthropy has awarded BCRF its highest possible rating of A+. BCRF is the only breast cancer organization in the U.S. to receive these accolades. For more information, visit www.bcrf.org.

Evening Reception Host - New Radiant Technology

New Radiant Technology is an Italian company, leader on the international market of IORT technique applications based on the acceleration of electrons. NRT carries out its operational activities in Apulia, where the Scientific Area Park is located, which includes the Research Centre, the Production Plant, the Technological Services Centre and the Training Centre. NRT invests in the research, design and development of innovative clinical technologies in the field of radiation therapy, becoming a reference for the world’s most advanced centers dealing with surgical oncology.


Al Badr: Founded in 1987 as a professional company in the Medical field. Our products covered hundreds of hospitals all over Egypt. We represent the Famous international companies in radiation therapy: PTW, Preoss, Orfit, Aleph Medical, Barry, and NTN. Our vision is to be the leading provider in the Middle East.
Sales Contract  Conference Code: DB LS 03

Please complete this form and fax back to
+ 91 80 3991 9099
or email to: tarun.rajagopal@fleminggulf.com

Registration Details  Please write in CAPITAL LETTERS

[ ] Ms  [ ] Mrs  [ ] Mr Surname: __________________________
Name: __________________________
Job Title: __________________________
Email: __________________________

[ ] Ms  [ ] Mrs  [ ] Mr Surname: __________________________
Name: __________________________
Job Title: __________________________
Email: __________________________

[ ] Ms  [ ] Mrs  [ ] Mr Surname: __________________________
Name: __________________________
Job Title: __________________________
Email: __________________________

Terms and Conditions:
Fleming Gulf requires the full payment within 5 days from receipt of invoice. Fleming Gulf reserves the right to refuse entry to any customer who has not paid their invoice. A credit card guarantee may be requested if full payment has not been received. All bookings carry a 50% liability after the booking has been made. There will be no refunds for cancellations received on or after one month before the start of the conference. If you decide to cancel after this date the full invoice remains payable.

Fleming Gulf reserves the right to change the content, timing, speakers or venue should circumstances require. The event may be postponed or cancelled due to acts of terrorism, war, extreme weather conditions, industrial action, acts of God or any event beyond the control of Fleming Gulf. If such a situation arises we will endeavour to reschedule the event. However, Fleming Gulf cannot be held responsible for any cost, damage or expenses which may be incurred by the customer as a consequence of the event being postponed or cancelled. Fee does not include travel, hotel accommodation, transfers or insurance.